- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06364514
PICNIC Study - PatIent Centered aNtIbiotic Courses in Children With Medical Complexity
April 9, 2024 updated by: Jonathan Mansbach, Boston Children's Hospital
To determine if clinicians can safely reduce antibiotic exposure in children with medical complexity (CMC) who are diagnosed with pneumonia by implementing an intervention that bases total antibiotic duration on an individual's clinical stability.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kathleen Snow, MD
- Phone Number: 6178238926
- Email: kathleen.snow@childrens.harvard.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Admitted to the Complex Care Service at Boston Children's Hospital with a provider diagnosis of pneumonia
- Started on antibiotics by the provider team
- Ages 2-25 years old
Exclusion Criteria:
- Patients initially admitted to the intermediate care unit or ICU due to increased respiratory support needs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Group
Patients will be started on antibiotics for treatment of pneumonia per usual care by their medical provider team.
The research team will monitor enrolled patients daily for markers of their clinical status (caregiver assessment of respiratory status, supplemental oxygen/respiratory support, presence of fever).
Once the patient has been "clinically stable" x48 hours, antibiotics will be discontinued.
|
Base total days of antibiotics on clinical stability vs utilizing predetermined total days of antibiotics
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of eligible patients who consent to participate in the intervention
Time Frame: 48 hours
|
Caregiver and medical provider acceptability
|
48 hours
|
Rate of persistent and worsening respiratory symptoms measured by patient's clinical status; the rate of emergency department revisit or hospital readmission within 1 week of antibiotic discontinuation
Time Frame: 1 week
|
Patient Safety Outcomes
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median days of antibiotics received for patients in the intervention group as well as from historical control group
Time Frame: 30 days
|
Pneumonia antibiotic duration
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2024
Primary Completion (Estimated)
July 1, 2025
Study Completion (Estimated)
October 1, 2025
Study Registration Dates
First Submitted
April 3, 2024
First Submitted That Met QC Criteria
April 9, 2024
First Posted (Estimated)
April 15, 2024
Study Record Updates
Last Update Posted (Estimated)
April 15, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-P00047313
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Avicenna Military HospitalCompletedHospital-acquired Pneumonia | Ventilator Associated Pneumonia | Community-acquired PneumoniaMorocco
Clinical Trials on Clinical Stability Assessment
-
Schulthess KlinikCompletedJoint Instability | Osteoarthritis Thumb | Arthrosis of First Carpometacarpal JointSwitzerland
-
Wafaa Mahmoud AminCairo UniversityCompletedOverweight and Obesity | Balance; DistortedSaudi Arabia
-
Cairo UniversityCompleted
-
University Hospital, GhentCompleted
-
Thomas Jefferson UniversityCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of BolognaCompleted
-
Florida International UniversityNational Institute of Mental Health (NIMH); University of MiamiCompletedDisruptive BehaviorUnited States
-
Universidad de ExtremaduraCompletedPostural Stability | Muscular ActivitySpain
-
Fondazione Don Carlo Gnocchi OnlusCompletedChronic Low-back PainItaly
-
Czech Technical University in PragueMayo Clinic; University Hospital, Montpellier; McGill University Health Centre... and other collaboratorsUnknownParkinson Disease | REM Sleep Behavior DisorderUnited States, Canada, Austria, Czechia, France, Germany, Italy